Test Price
2,800 AED✅ Home Collection Available
PRKAG2 Gene Wolff‑Parkinson‑White Syndrome Genetic Test 2800 AED
Executive Summary & Core Metrics
Diagnostic Precision: 99.9% diagnostic sensitivity achieved through ISO‑certified NGS processing and validated bioinformatics pipelines aligned with international genomic standards.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM, ensuring specimen integrity from draw to laboratory accession.
Clinical Guidance: Post‑test telephonic clinical correlation session with a DHA‑licensed Consultant Medical Geneticist, ensuring accurate interpretation of variant pathogenicity and family implications.
Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
This advanced Next‑Generation Sequencing (NGS) test analyses the entire coding region and conserved splice sites of the PRKAG2 gene to detect pathogenic or likely pathogenic variants responsible for Wolff‑Parkinson‑White (WPW) syndrome and associated glycogen‑storage cardiomyopathies. The assay provides comprehensive variant detection including single nucleotide variants (SNVs), small insertions and deletions (indels), and copy‑number variations (CNVs) across the genomic target region.
| Feature | Our Test (NGS) | Sanger Sequencing (Alternative) |
|---|---|---|
| Methodology | Massively Parallel NGS (Illumina platform) with 100 bp paired‑end reads, >200× mean coverage | Capillary electrophoresis single‑exon Sanger |
| Variant Detection | SNVs, indels, copy‑number variations (CNVs) – comprehensive | Only SNVs and small indels; CNV detection limited |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks (if sequential exon testing) |
| Price (AED) | 2800 | 2100–3200 (per gene) |
Physician Insight & Safety Protocols
"Genetic testing for PRKAG2-related WPW syndrome provides valuable molecular confirmation that must be interpreted alongside the clinical phenotype, ECG findings, and family history. A pathogenic variant does not automatically predict disease severity or progression. Results should always be correlated by a qualified medical geneticist in consultation with a cardiologist before any management decisions are made. Family cascade screening is strongly recommended when a pathogenic variant is identified."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory on Genetic Test Interpretation
Important Clinical Considerations
A negative genetic result does not exclude WPW syndrome if characteristic delta waves are present on ECG. Conversely, a positive result indicates increased risk but does not confirm current or future disease expression. All treatment decisions including the use of antiarrhythmic medications, beta‑blockers, or catheter ablation must be made by your treating cardiologist. Do not alter or discontinue any prescribed therapy based solely on genetic findings.
Exclusion Criteria & Emergency Red Flags
- Active febrile illness or haemodynamic instability: Home collection should be postponed until stable.
- Known bleeding diathesis or severe thrombocytopenia: Phlebotomy requires medical clearance.
- Recent blood transfusion (within 7 days): May interfere with germline DNA extraction – reschedule.
- Emergency Red Flags: If you experience palpitations with syncope, severe chest pain, or sudden shortness of breath, call 998 immediately; do not wait for test results.
Patient FAQ & Clinical Guidance
1. What does the PRKAG2 genetic test detect, and can it confirm I have WPW syndrome?
This test identifies pathogenic variants in the PRKAG2 gene that cause glycogen‑storage cardiomyopathy and ventricular pre‑excitation, providing molecular confirmation of WPW syndrome when correlated with a clinical ECG. A positive result supports the diagnosis; however, WPW is a clinical and electrophysiological entity, so a negative genetic finding does not exclude the syndrome if characteristic delta waves are present.
2. How is the sample collected, and do I need a fasting state?
A trained phlebotomist collects a standard whole‑blood sample in an EDTA tube from your home, office, or hotel (8 AM–11 PM), following temperature‑controlled cold‑chain protocols. No fasting is required for genomic DNA extraction.
3. What happens after the test is completed?
Once the NGS analysis and clinical interpretation are finalised (3–4 weeks), you will receive a comprehensive report with pathogenicity classification and a scheduled tele‑consultation with a Consultant Medical Geneticist to explain the results, implications for family screening, and personalised management under DHA supervision.
4. Will my insurance cover this genetic test?
Coverage varies by insurer and policy. Our team can verify your direct billing eligibility via WhatsApp at +971 54 548 8731. Prior approval may be required for genetic testing under some plans.
UAE Regulatory & Data Privacy Adherence
Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – All genomic and personal data are processed, stored, and transmitted in full compliance with PDPL requirements for consent, purpose limitation, and data subject rights.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – Our digital health infrastructure, including electronic health records and tele‑consultation platforms, adheres to the security and interoperability standards mandated by this law.
Federal Decree-Law No. 4 of 2016 on Medical Liability – Clinical oversight, patient consent protocols, and reporting of genetic findings follow the framework established by this law to ensure patient safety and professional accountability.
Clinical & Logistical Metadata
| Test Name | PRKAG2 Gene Wolff‑Parkinson‑White Syndrome Genetic Test |
| Price (AED) | 2800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina Platform, Paired‑End 100 bp Reads, >200× Mean Coverage |
| ICD-10-CM Code | I45.6, I42.7 |
| LOINC Code | 94219-5 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians